Weight-Loss Maintenance

The trial found that orforglipron maintained significantly more prior weight loss than placebo in both cohorts. Switching to orforglipron maintained nearly all semaglutide-associated weight loss and most tirzepatide-associated weight loss. Among plateau participants, maintenance was 75% versus 49% after tirzepatide and 79% versus 38% after semaglutide. Cohort 2 participants assigned only to orforglipron regained about 1 percentage point or about 1 kg from ATTAIN-MAINTAIN baseline by week 52. Cohort 1 participants assigned only to orforglipron regained about 5 percentage points or about 5 kg from ATTAIN-MAINTAIN baseline by week 52. The cited literature frames losing weight and maintaining weight loss as biologically different challenges. The cited adipose tissue literature includes mechanisms for weight regain and epigenetic memory after obesity. The cited reference list emphasizes that maintaining weight loss can be difficult after pharmacological treatment stops. The study focuses on maintaining weight loss after weight reduction in people with overweight or obesity.